Vitamins such as anticancer shield

Unlike carbohydrates, fats and proteins, vitamins are not an energy source, but also serve as chemical models for enzymes related to metabolic function, cell production, tissue repair and other vital processes.

Vitamin C, and precursor of vitamin A as beta-carotene, are antioxidants, and hence are considered as protectors of the oxidation of cells, and thus of degenerative diseases such as cancer.

Protein HLJ1 slowing the progression lung cancer

An investigation identified a protein that may curb lung cancer. HLJ1 protein is involved in slowing the progression of lung cancer, the researchers said.
Scientists at the National Taiwan University (China) have concluded that a protein called HLJ1 could function as tumor suppressor in non-small cell lung cancer.

The study, published in the Journal of the National Cancer Institute was based on increasing or blocking HLJ1 expression in lung carcinoma cells, and gene expression observed in tumors and adjacent tissue cells in 71 patients with cancer NSCLC.

Stanford bans gifts from drug companies, including pens

Medical Center Stanford University banned their doctors accept gifts (including children) from representatives of pharmaceutical companies, under a new policy that seeks to limit industry influence on patient care and medical education.

The new rules, to be announced today, are part of a growing trend among academic medical centers. Yale and the University of Pennsylvania, for example, have announced similar policies.

Melanoma vaccine

Hundred percent development argentinoUna melanoma vaccine ready for final test Will be tested in 108 patients with skin cancer, would be available in 3 or 4 years.

Argentine researchers have developed a vaccine to treat melanoma, the most common form of cancer in people aged between 15 and 44 years will begin in the coming months with phase studies in patients prior to approval by authorities local regulatory. If you pass this last test, called Vaccimel vaccine could be available in 3 to 4 years. "After three years of receiving the vaccine, 70% of patients in advanced stages of melanoma who participated in clinical studies so far remained free of disease," said Dr. Marcela Barrio, CONICET researcher involved in the development of Vaccimel, during a press conference held in Expo-Medical.

Treatment of neutrophils by Antonio Bru

In 1993, Doctor in Physics Antonio Bru works in the CIEMAT, the Ministry of Education and Science ...

Enjoy a contract under the project, and his work focuses on hydration fronts in heterogeneous materials, forming part of a containment of high level radioactive waste. In his paper studies the phenomena of molecular diffusion of a medium in another, and building on similarities that sometimes have physical and biological phenomena of very different nature, almost like a mathematical curiosity, became interested in the dynamics of tumor growth. He realizes that in its opinion:

Information on Neupogen

Composition: Vial: Each 1 ml vial contains: Filgrastim 30 million IU equal to 300 mcg. Preloaded Syringe: Each pre-filled syringe of 1 ml contains 30 million IU Filgrastim equal to 300 mcg ...

Therapeutic Action: Human factor granulocyte colony stimulating recombinant (Filgrastim or rHuG-CSF).

Directions: So the main uses of Neupogen (G-CSF) at present are: treatment of febrile neutropenia induced by cancer chemotherapy standard. Neupogen (G-CSF) reduces the intensity and duration of neutropenia straight to anticancer chemotherapy and reduces the incidence, duration and severity of infections that accompany the neutropenia in these patients. Treatment of neutropenia from chemotherapy with autologous bone marrow transplantation. Treatment of chronic congenital neutropenia, idiopathic, cyclic neutropenia in children and caused by radiation therapy, steroids, antiinflammatory, antithyroid drugs, AZT, and drugs in general. In patients with infection and leucopenia Neupogen can help bone marrow recovery.

FAQ Bru therapy

What is therapy?
The therapy is cause neutrophilia (neutrophil count elevation) in the vicinity of the patient's tumors ...


Neutrophils are immune cells that, unlike other body cells, supporting the acidic environment generated by the tumor environment. According to the work of A. Bru, these cells are capable of exerting pressure on the tumor. Tumor cells pressurized first enter a quiescent state, which do not divide, and then die by necrosis. To cause neutrophilia is injected the patient Neupogen ®.

Yondelis: surprise in the cancer group

For some patients Yondelis is almost a miracle. "Dr. Robert Maki, an oncologist at Memorial Sloan Kettering Cancer Center in New York and an expert in sarcoma, is unequivocal in his opinion on the ET-743 ...

"There is a percentage of patients on regular medication which had not achieved anything and they are alive thanks to him, "he says. For Maki, now the challenge is to know why Yondelis is definitive in some sarcomas, whereas in others the response is much less clear.